Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05016804 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 2025 to Nov 2026
    • Study sites: 3 to 2
    v6
  2. Start date: Feb 1, 2022 to Jul 4, 2022v5
  3. Study description expanded, about 30 wordsv4
  4. Study sites: 1 to 3
    • Start date changed from estimate of Feb 2022 to Feb 1, 2022
    v3
  5. Start date: Nov 2021 to Feb 2022
    • Site contact updated
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Systemic Sclerosis
Trial Details
NCT Number NCT05016804
Lead Sponsor The Foundation for Orthopaedics and Regenerative Medicine
Conditions
(from sponsor)		 Systemic Sclerosis
Related terms Scleroderma, Diffuse, Scleroderma, Systemic
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov